Why I Use Subcutaneous Immunoglobulin (SCIG)
- 762 Downloads
Immunoglobulin (IgG) replacement is a life-saving treatment for individuals with primary immunodeficiency disease (PIDD). Today, there are many options for IgG replacement, and the choice is an individual one based on many factors. My preference for most patients is the subcutaneous (SCIG) route. It offers many advantages not offered by the intravenous (IVIG) route. These include: 1) independence from hospital-based infusion settings; 2) an alternative for patients with poor venous access; 3) better tolerability in those patients who are not able to tolerate IVIG; 4) flexibility of dosing; 5) ease of administration; 6) a very low side-effect profile; 7) a comparatively more even, almost physiological, IgG level; 8) less cost to administer than IVIG; and 9) improved quality of life in patients treated with SCIG compared with those treated with IVIG. For most patients with PIDD who require IgG replacement, SCIG offers advantages not available with IVIG.
KeywordsIgG IgG replacement therapy subcutaneous bronchiectasis autoimmune disease
Conflict of interest
The author serves on advisory boards and as a consultant to CSL Behring, Baxter, DNAX, and Virapharma. He is a principal investigator for CSL Behring, Baxter, and Virapharma.
- 3.Hizentra, Immune Globulin Subcutaneous (Human), 20 % Liquid. CSL Behring AG, Bern, Switzerland; March 1, 2010. Available at: http://www.hizentra.com/docs/hizentraPI.pdf. Accessed Nov. 16, 2012.
- 4.GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10 % Solution, for intravenous and subcutaneous administration. Westlake Village, CA: Baxter Healthcare Corporation; 2012. Available at: http://www.baxter.com/products/biopharmaceuticals/downloads/gamliquid_PI.pdf. Accessed Nov. 16, 2012.
- 5.Vivaglobin (Immune Globulin Subcutaneous [Human]). CSL Behring GmbH; 2006. Available at: http://www.cslbehring.com/docs/31/247/Vivaglobin%20April%2010%20PI,0.pdf. Accessed Nov. 16, 2012.
- 10.Asia Pacific Immunoglobulins in Immunology Expert Group. Consensus Recommendations for the use of Immunoglobulin Replacement Therapy in Immune Deficiency. 2009. Available at: http://www.info4pi.org/Documents/Publications/APIIEG%20Consensus%20Recommendations%20Edition%202%20July%202009_20120201_170745.pdf. Accessed Nov. 16, 2012.